Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy

•42% of women with stage I carcinosarcoma received no adjuvant chemotherapy or radiotherapy.•Lymphadenectomy, multiagent chemotherapy, and brachytherapy were each associated with increased survival.•Hazard of death decreased 3% (1–5%) per each 5 lymph nodes removed up to 15–20 removed nodes.•Hazard of death increased 5% (4–7%) per each 1cm increase in tumor size.